Transplant News and Research RSS Feed - Transplant News and Research

Captisol-enabled Melphalan meets primary end points in phase 2 pivotal trial

Captisol-enabled Melphalan meets primary end points in phase 2 pivotal trial

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that its pivotal trial of Captisol-enabled (propylene glycol-free) Melphalan met its primary end points. [More]
Alexion Pharmaceuticals obtains orphan drug designation from EC for Soliris

Alexion Pharmaceuticals obtains orphan drug designation from EC for Soliris

Alexion Pharmaceuticals, Inc. today announced that the European Commission has granted an orphan drug designation (ODD) to Soliris (eculizumab), a first-in-class terminal complement inhibitor, for the prevention of graft rejection following solid organ transplantation. Graft rejection can cause severe injury to the transplanted organ and is a significant barrier to successful transplantation. [More]

VHVI implants miniaturized HeartWare HVAD Pump through minimally invasive approach

Sometimes smaller is better. This is especially true of left ventricular assist devices, the mechanically operated heart pumps that are implanted in heart failure patients to bridge them to transplantation. [More]
Pfizer reports positive results from two tofacitinib Phase 3 trials for moderate-to-severe plaque psoriasis

Pfizer reports positive results from two tofacitinib Phase 3 trials for moderate-to-severe plaque psoriasis

Pfizer Inc. announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), evaluating the efficacy and safety of tofacitinib, an oral Janus kinase (JAK) inhibitor, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis. [More]

Stool color guide and free mobile app help diagnose liver-ravaging disorder in babies

Fecal color and consistency are well-known markers of digestive health in both children and adults, but paying attention to a newborn's shade of poop can be a decided lifesaver in babies born with the rare, liver-ravaging disorder biliary atresia, commonly heralded by white or clay-colored stool. [More]
Study suggests that improving newborns' bacterial environment could fend off infections

Study suggests that improving newborns' bacterial environment could fend off infections

Mothers give a newborn baby a gift of germs-germs that help to kick-start the infant's immune system. But antibiotics, used to fend off infection, may paradoxically interrupt a newborn's own immune responses, leaving already-vulnerable premature babies more susceptible to dangerous pathogens. [More]

Le Bonheur Children's takes aggressive steps to minimize blood loss during heart surgery

More than 20 percent of Le Bonheur Children's Hospital's open heart surgeries are now bloodless, meaning no blood or blood products given during surgery. The Memphis, Tenn., hospital's Heart Institute has been taking aggressive steps to minimize blood loss during surgery and reduce perioperative blood transfusions over the last 18 months. [More]

Docs who treat patients with severe LAM face agonizing treatment decision

​Doctors who treat patients with a severe and progressive respiratory disease called lymphangioleiomyomatosis (LAM) can face an agonizing treatment decision. [More]

iGetBetter joins Massachusetts Hospital Association to reduce hospital readmissions

iGetBetter, a supplier of post-acute care transition solutions designed to help reduce hospital readmissions, and the Massachusetts Hospital Association (MHA), the primary representative of the hospital community in the commonwealth, announced today that iGetBetter will join MHA and contribute to efforts now underway by Massachusetts hospitals to improve post-discharge care transition and reduce hospital readmissions. [More]
MD Anderson honors America's future cancer leaders

MD Anderson honors America's future cancer leaders

The University of Texas MD Anderson Cancer Center this week honored 16 junior faculty members who are expected to become some of America's future cancer leaders. The faculty members are the first R. Lee Clark Fellow award winners. The new award was established to recognize outstanding work by junior faculty members and to help support their future efforts. [More]

Harvard successfully transplants regenerated esophagus into rat using bioreactor

Harvard Apparatus Regenerative Technology, Inc., a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, announces that a research team led by Paolo Macchiarini, MD, PhD at Karolinska Institutet in Sweden has successfully transplanted a regenerated esophagus into a rat using a bioreactor developed by HART. [More]

Obeticholic acid meets primary composite endpoint in Phase III study

Results from an international Phase III study presented today at the International Liver CongressTM 2014 have shown obeticholic acid (OCA) given to patients suffering from Primary Biliary Cirrhosis (PBC) who previously had an inadequate response to, or have been unable to tolerate ursodeoxycholic acid (UDCA), produced meaningful biochemical and clinical improvements. UDCA is the only therapy currently approved to treat PBC. [More]
Oral therapy cures hepatitis C infection in more than 90% of patients with liver cirrhosis

Oral therapy cures hepatitis C infection in more than 90% of patients with liver cirrhosis

Twelve weeks of an investigational oral therapy cured hepatitis C infection in more than 90 percent of patients with liver cirrhosis and was well tolerated by these patients, according to an international study that included researchers from UT Medicine San Antonio and the Texas Liver Institute. [More]

Adoptive T-cell therapy may help in treating liver cancer, says study

Significant new data presented today at the International Liver Congress- 2014 indicate that liver cancer (Hepatocellular Carcinoma (HCC)) may be treated by adoptive T-cell therapy. [More]

New research provides new hope for liver transplant patients with recurring hepatitis C

New research announced at the International Liver CongressTM 2014 today provides new hope for the notoriously difficult-to-treat population of liver transplant patients with recurring hepatitis C (HCV). [More]

Study shows impact of hepatic encephalopathy on liver disease patients

New data presented today at the International Liver Congress show the impact of hepatic encephalopathy on liver disease patients and healthcare systems. [More]

Inserm plays key role in developing European research

The French National Institute of Health and Medical Research (Inserm) is currently the leading biomedical research organisation in Europe, and plays a key role in developing European research. To mark its 50th anniversary, Inserm wanted to assess the perceptions of Europeans regarding biomedical research. [More]

Novel prediction model improves patient outcomes after paracetamol-induced acute liver failure

In the UK paracetamol toxicity is the most common cause of ALF and has a high mortality rate. It is estimated that 150 to 200 deaths and 15 to 20 LTs occur as a result of poisoning each year in England and Wales. [More]

Gilead Sciences announces positive results from LDV/SOF phase 2 studies on HCV infection

Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from two Phase 2 studies evaluating investigational all-oral regimens containing the nucleotide analog polymerase inhibitor sofosbuvir (SOF) for the treatment of chronic hepatitis C virus (HCV) infection. [More]

Restoration Robotics presents revolutionary robotic systems at Orlando Live Surgery Workshop

Restoration Robotics, Inc., the global leader in robotic hair transplantation, will have Craig Ziering, DO, present ARTAS Hair Studio™ and the ARTAS® Robotic System during the Platinum Orlando Live Surgery Workshop taking place April 9 through 12 in Orlando, FL. [More]